Nebenwirkungen · Invokana
Invokana 100 mg film-coated tablets Invokana 300 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 15
HOS-128166 · Präparat HOS-096517
In a long-term renal outcomes study of 4,397 treated adult subjects with type 2 diabetes and diabetic kidney disease, the incidence rates of all adjudicated bone fracture were 1.2 events per 100 patient- years of follow-up for both canagliflozin 100 mg and placebo. In other type 2 diabetes studies with canagliflozin, which enrolled a general diabetes population of 7,729 adult patients and where bone fractures were adjudicated, the incidence rates of all adjudicated bone fracture were 1.2 and 1.1 per 100 patient-years of follow-up to canagliflozin and control, respectively. After 104 weeks of treatment, canagliflozin did not adversely affect bone mineral density.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-18T14:12:00Z · SHA-256 7067553c5dc97aae664e9160409281edb3ba1df3f3d4e6376eabc1ce3744693b · Passage dd07f3ae083ecd2aa75a595958c3e7b3ccf130f0cb878f47ffcd9db835ea4bf1 · Zeichen 18282–18952 im Abschnitt